EuroPCR 2023 | TAVR in TAVR Results with Balloon-Expandable Valves

With the expansion of transcatheter aortic valve replacement (TAVR) use in the low-risk population, more patients will need repeat valve replacement in the future, making it paramount to understand the performance of repeat TAVR. Currently, this information is limited.

EuroPCR 2023 | ACURATE Neo2: Resultados a 5 años

The aim of this study was to analyze the real-world experience of performing a second TAVR using SAPIEN balloon-expandable valves. A second aim was to compare the safety and efficacy of repeat TAVR compared with initial TAVR, and to determine whether the results are dependent on the transcatheter heart valve (THV) index.

Of 348,338 patients who underwent TAVR with implantation of the EDWARDS balloon-expandable valve between 2011 and 2022, 1216 patients required a second TAVR. Out of these patients, 475 were in the Edwards THV index group and 741 patients were in the non-index THV group. Propensity score matching was used to homogenize the samples.

The primary endpoint (PEP) was death and stroke at 30 days and at 1 year. The secondary endpoint (SEP) was procedural, in-hospital, echocardiographic, and health status outcomes.

Read also: EuroPCR 2023 | Intravascular Lithotripsy (IVL) Balloon in the Treatment of Underexpanded Stents.

Mean patient age was 78 years old, and most subjects were male. The mean Society of Thoracic Surgeons (STS) score was 8.3 for the second TAVR group vs. 5.2 for the initial TAVR group (p < 0.01). In terms of the procedure, transfemoral access was the most common access in both groups, with similar success rates.

Regarding outcomes, there were no differences in the PEP at 30 days and 1 year. In turn, for the SEP, valve reintervention was significantly more frequent in the second TAVR group at 30 days and 1 year.

Conclusion

Performing new TAVR with balloon-expandable valves may be a reasonable therapeutic option for patients with failed initial TAVR. Long-term data are needed to stratify which type of valve is necessary in an initial scenario and which valve in a later scenario.

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Outcomes of repeat Transcatheter Aortic Valve Replacement with Ballon-expandable Valves.

Reference: R. Makkar et al.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

The Two Sides of the Coin: What Do CHAMPION-AF and CLOSURE-AF Teach Us About Left Atrial Appendage Closure?

Letter to the editor: Juan Manuel Pérez Asorey Percutaneous left atrial appendage closure (LAAO) is currently going through one of the most interesting stages of...

CLOSURE-AF: Percutaneous Left Atrial Appendage Closure versus Medical Therapy in Atrial Fibrillation

Percutaneous left atrial appendage closure has been proposed as an alternative to anticoagulation in patients with atrial fibrillation and high bleeding risk; however, comparative...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...